Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145039 · ClinicalTrials.gov registry record · NA
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02145039 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 2 participants.
The verdict
NCT02145039, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with advanced and/or high risk diseases.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- RADIATION Total Body Irradiation
- BIOLOGICAL Haploidentical stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02145039
The ClinicalTrials.gov registry entry for NCT02145039 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02145039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02145039 about?
NCT02145039 is a clinical study titled "Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases". This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with adv...
What is the current status of trial NCT02145039?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2014-10. Estimated completion is 2019-01.
What interventions are being tested in trial NCT02145039?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Total Body Irradiation (RADIATION), Haploidentical stem cell transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02145039?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.